LeadingAge is urging policymakers to consider a series of recommendations the group argues would cushion the blow of impending federal staffing minimums for the nursing home sector.
Sens. Bernie Sanders (I-VT) and Bill Cassidy (R-LA) on Thursday (Feb. 2) took up the mantle of Senate health committee chair and ranking member, respectively, kicking off a partnership that experts previously told Inside Health Policy will likely maintain the productive dynamic for which the committee is known.
Uninsured Americans enrolled in the optional Medicaid group offered by select states to cover COVID-19 vaccine, testing and treatments will lose their coverage once the public health emergency ends on May 11 unless the state decides to foot the bill, CMS told Inside Health Policy on Friday (Feb. 3).
LeadingAge is urging policymakers to consider a series of recommendations the group argues would cushion the blow of impending federal staffing minimums for the nursing home sector.
In separate letters sent to CVS and Walgreens, 20 Republican attorneys general warn the companies of the legal repercussions of sending abortion pills through the mail, coming a month after FDA announced it will allow mifepristone -- one of two pills used in the medication abortion regimen -- to be dispensed through certain pharmacies, including retail pharmacies, and will let the drug be prescribed via telehealth and delivered through the mail.
Illinois Democratic Sens. Dick Durbin and Tammy Duckworth have reached out to pharmacy chains Walgreens, CVS and Rite Aid to ask how the federal government can help ensure the stores have access to and can safely and confidentially provide patients with abortion pills now that FDA has cleared the way for pharmacies to get certified to dispense mifepristone -- one of two pills used as part of a medication abortion regimen -- in stores and by mail.
Senate Finance Committee Chair Ron Wyden (D-OR) is pressing CMS on how it will enforce the new drug pricing law’s requirement that drug makers pay rebates when they raise prices faster than the rate of inflation, saying he strongly hopes companies violating the requirement will be “penalized promptly.”
House Energy & Commerce oversight subcommittee Chair Morgan Griffith (R-VA) told Inside Health Policy he has already offered to work with FDA on creating a safe pathway to bring cannabidiol (CBD) products to market, just days after the agency on Jan. 26 said that the current food and dietary supplement frameworks won’t work for CBD, much to the chagrin of cannabis and dietary supplement groups.
The Infectious Diseases Society of America is eyeing the Pandemic and All Hazards Preparedness Act (PAHPA), a must-pass piece of legislation that’s up for reauthorization this year, as a potential vehicle for passing a key antibiotic funding bill that failed to make it into the fiscal 2023 omnibus spending package.
CMS on Wednesday (Feb. 1) projected in the 2024 advance rate notice that Medicare Advantage plans could see a pay bump of around 1% for 2024 – a sharp decrease from the more than 8% pay bump they received for 2023, as well as the 4% increase plans got for 2022. The smaller pay raise is due in part to CMS proposing a revamped risk adjustment model and changes in star ratings that are projected to hurt plan payments.
CMS released Wednesday (Feb. 1) an advance notice of changes to Medicare Part D payment policies plans will need to factor into their operations in 2024, most of which are measures enacted under the Inflation Reduction Act to lower out-of-pocket prescription drug costs for beneficiaries.
The Texas Medical Association is once again suing the Biden administration over its implementation of the No Surprises Act, this time arguing that CMS’ last-minute increase to the fees charged for using the independence dispute resolution process violates the Administrative Procedure Act.
The Senate Judiciary Committee will meet Thursday (Feb. 9) to take up five bipartisan bills aimed at lowering prescription drug costs by addressing common drug patent abuses and fostering better collaboration between FDA and the U.S. Patent and Trademark Office (USPTO).
Not a subscriber? Contact customer service at ihp@iwpnews.com or 703-416-8505. For a free trial, contact Steve Reilly.
A district court ruling on the fate of the Affordable Care Act’s preventive services coverage requirement is imminent now that the government and the plaintiffs in Braidwood v. Becerra have finished briefing on the scope of a relief in the high-profile case.
The American Hospital Association has asked to meet with CMS officials as they put together a regulation to repay hospitals for the 340B drug pay cuts the Supreme Court deemed unconstitutional, warning that any attempt by CMS to prospectively repay hospitals or to claw back funds from hospitals as it repays the 340B participants could lead to more lawsuits.
Rep. Larry Bucshon (R-IN) is calling for oversight hearings on Medicare physician pay reform as he works through stakeholders' comments on flaws in the system set up by the Medicare Access and CHIP Reauthorization Act to find solutions with bipartisan support, while a wide range of provider groups representing more than a million clinicians urge lawmakers to move on comprehensive reforms.
The Drug Enforcement Administration will propose regulations shortly that allow telehealth providers to continue prescribing controlled substances after the COVID-19 public health ends, a DEA official told Inside TeleHealth Tuesday afternoon (Jan. 31).
Covering the hottest new health policy debate in Washington -- in-depth reporting on the surging efforts to tackle social, racial and economic barriers to equitable health care.
Scorecard: 75% Of Insurers, PBMs Restrict Access To Autoimmune Meds
MedPAC Eyes Revamped Add-On Reform To Combat High Drug Costs In Part B
MACPAC Votes To Recommend Congress Let States Restrict Drug Coverage
© 2002-2023. Inside Washington Publishers | Contact Us
InsideHealthPolicy.com is a subscription-based news service. Access requires a subscription to one or more of our three areas of coverage (listed below), each of which includes both online and print components.
New: Health Exchange Alert - Daily news and analysis on the hottest issue in health care reform – federal and state requirements for the creation of health insurance exchanges.
Inside CMS - Covering Medicare and Medicaid from the inside out.
FDA Week - Exclusive reporting on the Food and Drug Administration's regulation of drugs, devices, food safety and related areas.
Sign up for one month of free, no-obligation access to InsideHealthPolicy.com.